Co-Founder And Chief Development Officer
Current
Dec 2019 - Present
AeroLeads people directory · profile
Stephen Cunningham Email & Phone Number
Co-Founder and Chief Development Officer
at
Engrail Therapeutics
1 work email found
@novartis.com
3 phones found area 973, 201, and 717
LinkedIn matched
✓ Verified May 2026
4 data sources
Profile completeness 100%
Current company
Role
Co-Founder and Chief Development Officer
Location
Basking Ridge, New Jersey, United States
Who is Stephen Cunningham? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Stephen Cunningham is listed as Co-Founder and Chief Development Officer at Engrail Therapeutics, based in Basking Ridge, New Jersey, United States. AeroLeads shows a work email signal at novartis.com, phone signal with area code 973, 201, 717, and a matched LinkedIn profile for Stephen Cunningham.
Stephen Cunningham previously worked as Executive VP and Chief Development Officer at Engrail Therapeutics and Co-Founder Engrail Therapeutics at Engrail Therapeutics. Stephen Cunningham holds Mb, Bch, B.A.O 1981, Md 1987, Mrcp 1985, Frcp 1996, Ffpm 1994, Medicine, Surgery, Obstetrics And Cardiology from Queen'S University Belfast.
Company email context
Email format at Engrail Therapeutics
This section adds company-level context without repeating Stephen Cunningham's masked contact details.
{first}.{last}@novartis.com
86% confidence
AeroLeads found 1 current-domain work email signal for Stephen Cunningham. Compare company email patterns before reaching out.
Profile bio
About Stephen Cunningham
Senior Leader Positioning Bio/Pharmaceutical Organizations to Capture Competitive Advantage Board of Directors | Chief Scientific Officer | Drug Development Leader | C-SuiteE: Lurgan@optonline.net Drug development expert with over 25 years of experience driving the development, launch, and lifecycle management of groundbreaking therapies, including ZESTRIL, ZESTORETIC, DIOVAN, SEROQUEL, TRILEPTAL, GILENYA, EXELON, ZOMETA, CASODEX, ARIMIDEX, ACCOLATE, FORADIL, and XOLAIR .Inspiring, authentic leader with extensive expertise bringing blockbuster therapies to market; broad experience spans multiple therapeutic areas including CVM, Neurology/CNS, Bone Health, Oncology, Women’s Health, and Respiratory health. An M&A strategist who structures organizations for optimal efficiency and performance, I am passionate about building organizations and cultures that foster excellence, challenging leaders to achieve peak performance, and driving metrics-based change. KEY STRENGTHS • Managing Regulatory Approval• Driving Launch Strategy• Engaging KOL’s• Developing Talent• Leading Change• Building Branded Portfolios• Cultivating InnovationCAREER HIGHLIGHTS INCLUDE• Advanced through senior-level roles in drug development at Zeneca and AstraZeneca, providing cross-portfolio international leadership for approval, launch, and lifecycle management of pioneering blockbusters.• As CSO at Novartis Corp, restructured drug development to align clinical development and medical affairs under six therapeutic areas and created a best-in-class clinical organization.• As board and executive advisor, played a key role high-value acquisitions, including Chase’s acquisition by Allergan in a deal worth up to $1B.
Listed skills include Clinical Development, Pharmaceutical Industry, Clinical Trials, Oncology, and 23 others.
Current workplace
Stephen Cunningham's current company
Company context helps verify the profile and gives searchers a useful next step.
15 roles · 37 years
Stephen Cunningham work experience
A career timeline built from the work history available for this profile.
Executive Vp And Chief Development Officer
Sep 2019 - Dec 2019
Co-Founder Engrail Therapeutics
Jul 2019 - Dec 2019
Advisor
Collaborating with the Cipla Technologies CEO to form a branded portfolio within the broader Cipla organization.
Feb 2018 - Aug 2019
Chief Scientific Officer & Head Of Scientific Affairs
Structured the organization to rapidly evolve and effectively support the global business, leading talent selection and strategy and managing portfolio of 250 products spanning a broad range of therapeutic areas. Helmed pharmaceutical development, technical operations, biopharmaceuticals, IP, regulatory affairs, project management, and innovation.
2015 - Jan 2018
Director And Member, Board Of Directors
Spearheaded development for lead compound through Phase II and played integral role in closing deal worth up to $1B with Allergan.
Jun 2013 - Dec 2016
Cso And Head Us Clinical Development And Medical Affairs
Aug 2000 - Sep 2013
Chief Scientific Officer & Head Of Us Clinical Development
Directed the US development organization, accelerating time-to-market while reducing costs by identifying and implementing opportunities for transformational change. Led development, launch, and lifecycle management across the portfolio, gaining approval for DIOVAN, ENTRESTO, GILENYA, RECLAST, STARLIX, ZELNORM, VISUDYNE, EXELON patch, XOLAIR, ZOMETA.
2010 - 2013
~3 yrs
Chief Scientific Officer And Head Of Us Clinical Development, Medical Affairs, & He/Or
Restructured the US drug development organization to create synergies between clinical development and medical affairs, integrating both under therapeutic areas to harmonize needs of payers, providers, and key customers at early stages.Built and led best-in class clinical development and medical affairs organization, which was pivotal to formulating.
2001 - 2010
~9 yrs
Vice President, Head Of Medical Affairs & He/Or
Led medical affairs organization in the US that comprised over 500 cross-functional team members. Identified opportunity to bridge gap between clinical and medical staff under a cohesive, unified vision.
2000 - 2001
~1 yr
Head Of Clinical & Medical Affairs, Canada
Directed drug development activities as head of all clinical/medical activities in Canada and member of senior leadership team. During tenure, led approval, launch, and/or lifecycle management of EXFORGE, LOTREL, SEROQUEL, ZOMIG, ZESTRIL, ZESTORETIC, ACCOLATE, ARIMIDEX, TOMUDEX and CASODEX.
1997 - 2000
~3 yrs
Head Of European Pharma Medical Managers, Zeneca
Led efforts across the portfolio, advising on global strategy and development in 14 countries spanning the Americas and Europe.
1995 - 1997
~2 yrs
Head Of Global Clinical Pharmacology
Restructured the organization and overhauled inefficient processes, expediting early development pathways to bring 30 translational candidates to Phase II readiness in 2 years.
1993 - 1995
~2 yrs
Head Of Neuroscience Medical Research, Europe
Drove clinical activities for blockbuster billion-dollar products: SEROQUEL and ZESTRIL/ZESTORETIC.
1992 - 1993
~1 yr
Drug Team Leader/Medical Advisor
Worked on high-value products including ZESTRIL, ZESORETIC, ZOMIG and SEROQUEL.
1989 - 1992
~3 yrs
1 education record
Stephen Cunningham education
-
Queen'S University Belfast
FAQ
Frequently asked questions about Stephen Cunningham
Quick answers generated from the profile data available on this page.
What company does Stephen Cunningham work for?
Stephen Cunningham works for Engrail Therapeutics.
What is Stephen Cunningham's role at Engrail Therapeutics?
Stephen Cunningham is listed as Co-Founder and Chief Development Officer at Engrail Therapeutics.
What is Stephen Cunningham's email address?
AeroLeads has found 1 work email signal at @novartis.com for Stephen Cunningham at Engrail Therapeutics.
What is Stephen Cunningham's phone number?
AeroLeads has found 3 phone signal(s) with area code 973, 201, 717 for Stephen Cunningham at Engrail Therapeutics.
Where is Stephen Cunningham based?
Stephen Cunningham is based in Basking Ridge, New Jersey, United States while working with Engrail Therapeutics.
What companies has Stephen Cunningham worked for?
Stephen Cunningham has worked for Engrail Therapeutics, Cipla, Pharmascience, Chase Pharmaceuticals, and Novartis.
How can I contact Stephen Cunningham?
You can use AeroLeads to view verified contact signals for Stephen Cunningham at Engrail Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Stephen Cunningham attend?
Stephen Cunningham holds Mb, Bch, B.A.O 1981, Md 1987, Mrcp 1985, Frcp 1996, Ffpm 1994, Medicine, Surgery, Obstetrics And Cardiology from Queen'S University Belfast.
What skills is Stephen Cunningham known for?
Stephen Cunningham is listed with skills including Clinical Development, Pharmaceutical Industry, Clinical Trials, Oncology, Lifesciences, Drug Development, Biotechnology, and Drug Discovery.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial